Development and validation of a three-long noncoding RNA signature for predicting prognosis of patients with gastric cancer

Table 3 Three-long noncoding RNA model and clinicopathologic parameters

Characteristic	Model
	High risk (%)	Low risk (%)	P value	χ2
Age, median, yr			0.11	0.74
≥ 60	52 (48.6)	55 (51.4)
< 60	43 (46.2)	50 (53.8)
Gender			0.27	1.23
Male	71 (50.0)	71 (50.0)
Female	24 (41.4)	34 (58.6)
Bormann type			0.00	14.29
I	2 (13.3)	13 (86.7)
II	36 (40.9)	52 (59.1)
III	56 (59.6)	38 (40.4)
IV	1 (33.3)	2 (66.7)
Tumor size			0.06	3.64
≥ 5 cm	48 (55.2)	39 (44.8)
< 5 cm	47 (41.6)	66 (58.4)
Location			0.77	0.52
Upper	23 (52.3)	21 (47.7)
Middle	26 (46.4)	30 (53.6)
Low	46 (46.0)	54 (54.0)
Lauren type			0.82	0.39
Intestinal	45 (47.4)	50 (52.6)
Mixed	23 (51.1)	22 (48.9)
Diffuse	27 (45.0)	33 (55.0)
Tumor differentiation			0.20	1.72
Moderate and well	27 (40.9)	39 (59.1)
Poor	68 (50.7)	66 (49.3)
Vessel invasion			0.54	0.38
Yes	30 (50.8)	29 (49.2)
No	65 (46.1)	76 (53.9)
Perineural invasion			0.06	3.52
Yes	30 (58.8)	21 (41.2)
No	65 (43.6)	84 (56.4)
TNM stage			0.01	10.85
I	13 (31.0)	29 (69.0)
II	18 (38.3)	29 (61.7)
III	63 (57.8)	46 (42.2)
IV	1 (50.0)	1 (50.0)

TNM: Tumor-node-metastasis.